These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

484 related articles for article (PubMed ID: 35135894)

  • 1. Comparative Effectiveness of mRNA-based BNT162b2 Vaccine versus Adenovirus Vector-Based Ad26.COV2.S Vaccine for the Prevention of COVID-19 among Dialysis Patients.
    Brunelli SM; Sibbel S; Karpinski S; Marlowe G; Walker AG; Giullian J; Van Wyck D; Kelley T; Lazar R; Zywno ML; Connaire JJ; Young A; Tentori F
    J Am Soc Nephrol; 2022 Apr; 33(4):688-697. PubMed ID: 35135894
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reports of Guillain-Barré Syndrome After COVID-19 Vaccination in the United States.
    Abara WE; Gee J; Marquez P; Woo J; Myers TR; DeSantis A; Baumblatt JAG; Woo EJ; Thompson D; Nair N; Su JR; Shimabukuro TT; Shay DK
    JAMA Netw Open; 2023 Feb; 6(2):e2253845. PubMed ID: 36723942
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of antibody response durability of mRNA-1273, BNT162b2, and Ad26.COV2.S SARS-CoV-2 vaccines in healthcare workers.
    Brunner WM; Freilich D; Victory J; Krupa N; Scribani MB; Jenkins P; Lasher EG; Fink A; Shah A; Cross P; Bush V; Peek LJ; Pestano GA; Gadomski AM
    Int J Infect Dis; 2022 Oct; 123():183-191. PubMed ID: 36044963
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative risk of thrombosis with thrombocytopenia syndrome or thromboembolic events associated with different covid-19 vaccines: international network cohort study from five European countries and the US.
    Li X; Burn E; Duarte-Salles T; Yin C; Reich C; Delmestri A; Verhamme K; Rijnbeek P; Suchard MA; Li K; Mosseveld M; John LH; Mayer MA; Ramirez-Anguita JM; Cohet C; Strauss V; Prieto-Alhambra D
    BMJ; 2022 Oct; 379():e071594. PubMed ID: 36288813
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative Effectiveness of Coronavirus Disease 2019 (COVID-19) Vaccines Against the Delta Variant.
    Risk M; Shen C; Hayek SS; Holevinski L; Schiopu E; Freed G; Akin C; Zhao L
    Clin Infect Dis; 2022 Aug; 75(1):e623-e629. PubMed ID: 35137006
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence of Severe COVID-19 Illness Following Vaccination and Booster With BNT162b2, mRNA-1273, and Ad26.COV2.S Vaccines.
    Kelly JD; Leonard S; Hoggatt KJ; Boscardin WJ; Lum EN; Moss-Vazquez TA; Andino R; Wong JK; Byers A; Bravata DM; Tien PC; Keyhani S
    JAMA; 2022 Oct; 328(14):1427-1437. PubMed ID: 36156706
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaccine-Associated Uveitis after COVID-19 Vaccination: Vaccine Adverse Event Reporting System Database Analysis.
    Singh RB; Parmar UPS; Kahale F; Agarwal A; Tsui E
    Ophthalmology; 2023 Feb; 130(2):179-186. PubMed ID: 36055601
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Durability of Heterologous and Homologous COVID-19 Vaccine Boosts.
    Tan CS; Collier AY; Yu J; Liu J; Chandrashekar A; McMahan K; Jacob-Dolan C; He X; Roy V; Hauser BM; Munt JE; Mallory ML; Mattocks M; Powers JM; Meganck RM; Rowe M; Hemond R; Bondzie EA; Jaegle KH; Baric RS; Schmidt AG; Alter G; Le Gars M; Sadoff J; Barouch DH
    JAMA Netw Open; 2022 Aug; 5(8):e2226335. PubMed ID: 35947380
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of CoronaVac, ChAdOx1 nCoV-19, BNT162b2, and Ad26.COV2.S among individuals with previous SARS-CoV-2 infection in Brazil: a test-negative, case-control study.
    Cerqueira-Silva T; Andrews JR; Boaventura VS; Ranzani OT; de Araújo Oliveira V; Paixão ES; Júnior JB; Machado TM; Hitchings MDT; Dorion M; Lind ML; Penna GO; Cummings DAT; Dean NE; Werneck GL; Pearce N; Barreto ML; Ko AI; Croda J; Barral-Netto M
    Lancet Infect Dis; 2022 Jun; 22(6):791-801. PubMed ID: 35366959
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neutralizing antibodies to SARS-CoV-2 variants of concern including Delta and Omicron in subjects receiving mRNA-1273, BNT162b2, and Ad26.COV2.S vaccines.
    Zhang GF; Meng W; Chen L; Ding L; Feng J; Perez J; Ali A; Sun S; Liu Z; Huang Y; Guo H; Gao SJ
    J Med Virol; 2022 Dec; 94(12):5678-5690. PubMed ID: 35902378
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity and Reactogenicity of Vaccine Boosters after Ad26.COV2.S Priming.
    Sablerolles RSG; Rietdijk WJR; Goorhuis A; Postma DF; Visser LG; Geers D; Schmitz KS; Garcia Garrido HM; Koopmans MPG; Dalm VASH; Kootstra NA; Huckriede ALW; Lafeber M; van Baarle D; GeurtsvanKessel CH; de Vries RD; van der Kuy PHM;
    N Engl J Med; 2022 Mar; 386(10):951-963. PubMed ID: 35045226
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Homologous and Heterologous Covid-19 Booster Vaccinations.
    Atmar RL; Lyke KE; Deming ME; Jackson LA; Branche AR; El Sahly HM; Rostad CA; Martin JM; Johnston C; Rupp RE; Mulligan MJ; Brady RC; Frenck RW; Bäcker M; Kottkamp AC; Babu TM; Rajakumar K; Edupuganti S; Dobrzynski D; Coler RN; Posavad CM; Archer JI; Crandon S; Nayak SU; Szydlo D; Zemanek JA; Dominguez Islas CP; Brown ER; Suthar MS; McElrath MJ; McDermott AB; O'Connell SE; Montefiori DC; Eaton A; Neuzil KM; Stephens DS; Roberts PC; Beigel JH;
    N Engl J Med; 2022 Mar; 386(11):1046-1057. PubMed ID: 35081293
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Humoral and cellular immunogenicity of homologous and heterologous booster vaccination in Ad26.COV2.S-primed individuals: Comparison by breakthrough infection.
    Hyun H; Jang AY; Park H; Heo JY; Seo YB; Nham E; Yoon JG; Seong H; Noh JY; Cheong HJ; Kim WJ; Yoon SY; Seok JH; Kim J; Park MS; Song JY
    Front Immunol; 2023; 14():1131229. PubMed ID: 36960070
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Seroresponse to SARS-CoV-2 Vaccines among Maintenance Dialysis Patients over 6 Months.
    Hsu CM; Weiner DE; Manley HJ; Aweh GN; Ladik V; Frament J; Miskulin D; Argyropoulos C; Abreo K; Chin A; Gladish R; Salman L; Johnson D; Lacson EK
    Clin J Am Soc Nephrol; 2022 Mar; 17(3):403-413. PubMed ID: 35144972
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative Immunogenicity and Effectiveness of mRNA-1273, BNT162b2, and Ad26.COV2.S COVID-19 Vaccines.
    Naranbhai V; Garcia-Beltran WF; Chang CC; Berrios Mairena C; Thierauf JC; Kirkpatrick G; Onozato ML; Cheng J; St Denis KJ; Lam EC; Kaseke C; Tano-Menka R; Yang D; Pavlovic M; Yang W; Kui A; Miller TE; Astudillo MG; Cahill JE; Dighe AS; Gregory DJ; Poznansky MC; Gaiha GD; Balazs AB; Iafrate AJ
    J Infect Dis; 2022 Apr; 225(7):1141-1150. PubMed ID: 34888672
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Herpetic Eye Disease After SARS-CoV-2 Vaccination: A CDC-VAERS Database Analysis.
    Singh RB; Parmar UPS; Ichhpujani P; Jeng BH; Jhanji V
    Cornea; 2023 Jun; 42(6):731-738. PubMed ID: 36706232
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-World Effectiveness and Immunogenicity of BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines in Patients on Hemodialysis.
    Sibbel S; McKeon K; Luo J; Wendt K; Walker AG; Kelley T; Lazar R; Zywno ML; Connaire JJ; Tentori F; Young A; Brunelli SM
    J Am Soc Nephrol; 2022 Jan; 33(1):49-57. PubMed ID: 34789546
    [TBL] [Abstract][Full Text] [Related]  

  • 18. COVID-19 Vaccine-Associated Uveitis in Patients With a History of Uveitis.
    Kim J; Kwon HY; Ahn SJ
    JAMA Ophthalmol; 2024 Jun; 142(6):522-528. PubMed ID: 38662361
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity Following Administration of BNT162b2 and Ad26.COV2.S COVID-19 Vaccines in the Pregnant Population during the Third Trimester.
    Citu IM; Citu C; Gorun F; Sas I; Tomescu L; Neamtu R; Motoc A; Gorun OM; Burlea B; Bratosin F; Malita D
    Viruses; 2022 Feb; 14(2):. PubMed ID: 35215900
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential immunogenicity of homologous versus heterologous boost in Ad26.COV2.S vaccine recipients.
    Khoo NKH; Lim JME; Gill US; de Alwis R; Tan N; Toh JZN; Abbott JE; Usai C; Ooi EE; Low JGH; Le Bert N; Kennedy PTF; Bertoletti A
    Med; 2022 Feb; 3(2):104-118.e4. PubMed ID: 35072129
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.